Molecular Cell, Volume 53

## Supplemental Information

## Largen: A Molecular Regulator

## of Mammalian Cell Size Control

Kazuo Yamamoto, Valentina Gandin, Masato Sasaki, Susan McCracken, Wanda Li, Jennifer Liepa Silvester, Andrew J. Elia, Feng Wang, Yosuke Wakutani,
Roumiana Alexandrova, Yathor D Oo, Peter Mullen, Satoshi Inoue, Momoe Itsumi, Valentina Lapin, Jillian Haight, Andrew Wakeham, Arda Shahinian, Mitsuhiko Ikura, Ivan Topisirovic, Nahum Sonenberg, and Tak W. Mak


D









$\begin{array}{ll}-\operatorname{Rap}(-) / \operatorname{Dox}(-) & \text { — } \operatorname{Rap}(-) / \operatorname{Dox}(+) \\ — \operatorname{Rap}(+) / \operatorname{Dox}(-) \quad \text { Rap (+)/Dox (+) }\end{array}$

- Unsorted - Single cell clone
..... Unsorted + RAP
.... Single cell clone + RAP
- Single cell clone + DOX
- Single cell clone + RAP + DOX

E


## Figure S1, related to Figure 1

(A) Rapamycin (RAP) induces cell size reduction. Jurkat cells were cultured in the presence of 20 nM RAP for 1, 2 or 3 days and cell size distribution was determined by flow cytometry. Inset numbers are the mean cell diameter for each group. $\Delta$, calculated \% difference between RAP-treated and untreated cells. (B) Repeated sorting increases the "stay-large" population in bulk cell clones. Solid black lines represent the size distribution of unsorted control cells. Solid red lines in the $1^{\text {st }}$ Sort columns represent the size distribution of RAP-treated cells. The top $<2 \%$ largest cells were isolated ( $1^{\text {st }}$ Sort) from among these RAP-treated cells and expanded in culture until they reached $>1 \times 10^{7}$. RAP treatment was repeated and the top $<2 \%$ largest cells were again recovered by flow cytometric sorting ( $2^{\text {nd }}$ Sort). These steps were repeated two more times to generate the $3^{\text {rd }}$ and $4^{\text {th }}$ Sorts. (C) Flow cytometric measurement of the cell size distribution of bulk clones after the $4^{\text {th }}$ sorting cycle $\left(\right.$ RF2 $/ 4^{\text {th }}$ ) and culture in the absence $(-)$ or presence $(+)$ of RAP and/or DOX, as indicated. (D) Different single cell clones show different cell size responses to RAP. Solid and dashed grey lines represent size distributions of parental Jurkat cells in the absence or presence of RAP, respectively. Solid and dashed black lines represent size distributions of representative single cell clones in the absence or presence of RAP, respectively. Red and green lines indicate size distributions of single cell clones treated with DOX in the absence or presence of RAP, respectively. (E) Comparison of cell volumes of G1 phase-gated cells. Control and Largen-O/E cells were gated to detect cells in G1 phase, and cell volumes were measured electronically.

A
B



- Vector
_ Myc-PRR16


## E


_ siCONTROL
siPRR16\#3
siPRR16\#3


G
siCONTROL

C


$$
\frac{R a p}{\text { Vec }} \frac{-\quad+}{\mathrm{L} 1} \frac{-\quad+}{\mathrm{L} 2}
$$

F


## Figure S2, related to Figure 2

(A) Immunoblot of cell lysates prepared from Jurkat cells stably transformed by infection with retrovirus expressing GFP (lane 1) or GFP-Largen (PRR16) fusion protein (lane 2). The indicated proteins were detected using anti-GFP antibody. (B) Flow cytometric determination of cell size distribution of (top) HeLa cells transiently transfected with plasmid expressing Myc-tagged Largen or vector control, and (bottom) 293T cells stably transformed with Myc-tagged Largen or vector control. Inset numbers are the mean forward scatter (FSC) values for each group. (C) Cell volumes of two independent 293T cell clones overexpressing Prr16 (L1 and L2), as well as a control clone transformed with the empty vector (Vec), cultured with/without RAP. Numbers are the mean cell volume in picolitres $\pm$ SD of 3 independent measurements using a Moxi $Z$ cell counter. ( ${ }^{*} p<0.05$, ** $p<0.001$ ) (D) Semi-quantitative RT-PCR of total RNA prepared from untransfected U2-OS cells (-) or U2-OS cells transfected with non-targeting control siRNA (C), or one of 4 PRR16/Largen siRNAs, each of which targeted a different site in the PRR16/Largen mRNA (\#1-\#4). Unless otherwise noted, siRNA\#3 was used for all experiments described in the main text. (E) Flow cytometric measurement of cell size distribution of (top) HeLa and (bottom) 293T cells transiently transfected with siRNA against PRR16/Largen (\#3) or with non-targeting siControl. Inset numbers are the mean FSC values for each group. (F) Cell volumes of Jurkat cells transiently transfected with siRNA against PRR16/Largen (\#3) or with non-targeting siControl. Numbers are the mean cell volume in picolitres $\pm$ SD of 4 independent measurements using a Moxi $Z$ cell counter. ( ${ }^{*} p<0.05$ ) (G) Flow cytometric
determination of apoptosis of U2-OS cells transfected with siRNA\#3 against PRR16/Largen or with non-targeting siControl. Transfected cells were incubated with FITC-conjugated Annexin V followed by staining with propidium iodide (PI).


## Figure S3, related to Figure 2

Comparison of the primary structures of Largen proteins among vertebrates. Amino acid sequences of human Largen and its orthologues from chimpanzee, rat, mouse, zebrafish, bovine, and chick are aligned. A dash ‘-‘ indicates that the orthologue has the same amino acid present in the same position as the human sequence. Differences in amino acids at a given position are shown for each orthologue. A gap indicates that there is no corresponding amino acid in the human sequence at the position where an orthologue has an extra amino acid or vice versa. Prolines are marked in red in the human sequence and in yellow in the orthologue sequences.

A


## Figure S4, related to Figure 3

(A) Phosphorylation status of molecules in the mTOR signaling pathway. Jurkat and 2D10 cells were serum-starved overnight in the absence (-) or presence (+) of DOX. Cells were further treated for 1 hr with vehicle (-), RAP (Rap, 20 nM ), or LY294002 (LY, $50 \mu \mathrm{M}$ ) prior to stimulation by serum. Lysates were prepared either before (0') or after 30 min incubation and immunoblotted as described above. $\alpha$-tubulin, loading control. (B) Immunoblot of proteins eluted from anti-Myc Ab-conjugated beads that were incubated with lysates of 293T cells transfected with empty vector (Vector), or plasmid expressing Myc-tagged Largen (myc-LARGEN) or Myc-tagged PRAS40 (myc-PRAS40; control). Proteins in the input, and proteins eluted from the beads using Myc-peptides, are shown for each lysate. $\beta$-actin, loading control. Results are representative of 3 experiments.


## Figure S5, related to Figure 4

(A) UV absorption profiles of ribosomes from control and Largen-O/E cells. Cytoplasmic extracts were fractionated by sucrose gradient sedimentation with continuous monitoring of absorbance at 254 nm . Fractions containing light polysomes (1-3 ribosomes per mRNA molecule) or heavy polysomes (>4 ribosomes per mRNA) were collected and applied to microarray analysis. Results are expressed as arbitrary units (AU) and are representative of multiple sedimentations. (B) Pie graph representation of 251 transcripts enriched in heavy polysome fractions of 2D10 cells as determined by differential microarray analysis of the fractions in (A). Transcripts are categorized by primary biological function. Numbers are the number of genes in each category. (C) Polysome profiles of control and Largen-O/E cells cultured in the presence of RAP. Measurement and analysis were performed as in (A). (D) The intensity of each band in the immunoblots in Figure 4C was quantitated by Image-J and the values were normalized against that of $\alpha$-tubulin. Results are the mean $\pm$ SD of values relative to untreated controls $(n>3) .\left({ }^{*} p<0.05,{ }^{* *} p<0.001\right)$. (E) Immunoblot of the indicated mitochondrial proteins in extracts of purified mitochondria from control or 2D10 cells with/without DOX. Results are representative of $>3$ trials.

A



B


C



D


## Figure S6, related to Figure 7

(A) Growth rate in cultures of (left) Jurkat, 2D10 and 3B3 cells, and (right) 293T clones stably transformed with empty vector (V7) or plasmid expressing Myc-tagged Largen (L1 and L2). Cell density was measured daily. Data are the mean $\pm$ SD of $>3$ independent measurements. (B) Cell volumes (left) and proliferation rates (right) of Jurkat and 2D10 cells cultured in glucose-depleted medium with/without DOX. Data are the mean $\pm$ SD of 3 independent experiments. (**p<0.001). (C) Cell cycle analysis of Jurkat and 2D10 cells treated with/without DOX. Cells were seeded at $2.5 \times 10^{5} / \mathrm{ml}$ and cultured overnight in the presence (+) or absence (-) of $1 \mu \mathrm{~g} / \mathrm{ml}$ DOX. The percentages of the total cell population that were in the G0-G1, S or G2/M phases were determined by flow cytometry. Results are the mean percentage of two independent assays. (D) Protein degradation profiles of parental 293T cells, 293T cells stably transformed with control plasmid (V1), and three independent 293T clones stably transformed with Myc-tagged Largen (L1, L2, L3). Cells were cultured in labeling medium plus [ ${ }^{35}$ S]-methionine for 30 min as described in EXPERIMENTAL PROCEDURES. Labeled cells were washed and cultured in standard medium for the indicated times. Cell lysates were prepared and equal amounts of total protein were fractionated by SDS-PAGE followed by autoradiography. Relative amounts of [ ${ }^{35}$ S]-methionine-labeled proteins were quantitated by densitometric scanning with Image-J. The relative density of radiolabeled proteins in each lane was normalized to that of the initial (time 0) sample for each cell line.

Table S1 Identification and mapping of the candidate genes in single cell clones, related to Figure 1

| Screen | ERM-tag | Clone ID | Intergenic integration ${ }^{*}$ | Intragenic integration | CC ${ }^{\text {2 }}$ |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Pilot | RF2 | $\begin{array}{\|l\|l\|} \hline 1 \mathrm{~A} 2 \\ 1 \mathrm{C} 2 \\ 2 \mathrm{~A} 1 \\ 2 \mathrm{~A} 2 \\ 2 \mathrm{~B} 1 \\ 2 \mathrm{~B} 4 \\ \hline \end{array}$ | Myc proto-oncogene protein / Gasdermin-C <br> Myc proto-oncogene protein / Gasdermin-C <br> POU class 5 homeobox 1B/myc proto-oncogene protein <br> Myc proto-oncogene protein / Gasdermin-C | C1orf186 <br> Cellular nucleic acid-binding protein isoform 1 | $\begin{aligned} & \hline 8 q 24.2 \\ & 1 q 32.1 \\ & 8 q 24.2 \\ & 8 q 24.21 \\ & 3 q 21 \\ & 8 q 24.2 \\ & \hline \end{aligned}$ |
|  |  | $\begin{aligned} & 2 C 1 \\ & 2 D 10 \\ & 3 B 2 \\ & 3 B 3 \\ & 3 B 4 \\ & \hline \end{aligned}$ | Proline-rich protein 16 / Ferritin mitochondrial <br> Prostaglandin D2 receptor 2 / Zona pellucida glycoprotein 1 <br> Proline-rich protein 16 / Ferritin mitochondrial <br> POU class 5 homeobox 1B / myc proto-oncogene protein | Triple functional domain protein | $\begin{array}{\|l} \hline 5 q 15.2 \\ 5 q 23.1 \\ 11 q 12.2 \\ 5 q 23.1 \\ 8 q 24.21 \\ \hline \end{array}$ |
| Core | Normal1 | $\begin{aligned} & \hline 1 \mathrm{C} 6 \\ & \text { 1D2 } \\ & \hline \end{aligned}$ |  | Down syndrome critical region protein 3 GNPTAB | $\begin{array}{\|l\|} \hline 21 q 22.2 \\ 12 q 23.2 \\ \hline \end{array}$ |
|  | Normal2 | $\begin{array}{\|l\|} \hline 1 \mathrm{~A} 1 \\ 1 \mathrm{~B} 6 \\ \text { 1C1 } \\ \text { 2B5 } \\ \hline \end{array}$ | NACC family member 2 / C9orf69 <br> Myc proto-oncogene protein / Gasdermin-C CD83 / Jumonji, AT rich interactive domain 2 protein | Adenylate cyclase activating polypeptide 1 | $\begin{array}{\|l} 9 q 34.3 \\ 8 q 24.2 \\ 6 p 23 \\ 18 p 11 \\ \hline \end{array}$ |
|  | Normal3 | $\begin{aligned} & 1 \mathrm{~A} 1 \\ & 1 \mathrm{~A} 3 \\ & 1 \mathrm{~B} 5 \\ & 1 \mathrm{C} 1 \\ & 1 \mathrm{C} 2 \\ & 1 \mathrm{D} 1 \\ & \hline \end{aligned}$ | Methionine adenosyltransferase II, beta / Teneurin-2 | Mucin 4 <br> Myocyte-specific enhancer factor 2C isoform 1 <br> PR domain containing 8 <br> Metastasis-associated protein MTA1 <br> Myocyte-specific enhancer factor 2C isoform 1 | $\begin{aligned} & \hline 3 q 23 \\ & 5 q 14 \\ & 4 q 21 \\ & 5 q 34 \\ & 14 q 32.3 \\ & 5 q 14 \\ & \hline \end{aligned}$ |
|  | NLS1 | $\begin{array}{\|l\|} \hline 1 \mathrm{~A} 6 \\ \text { 1D5 } \\ \text { 1B2 } \\ \text { 1D1 } \\ \text { 1D3 } \\ \text { 2A6 } \\ \hline \end{array}$ | Rho GDP-dissociation inhibitor 2 / Phosphodiesterase 6H Rho GDP-dissociation inhibitor 2 / Phosphodiesterase 6H <br> Gamma-glutamyltransferase light chain 1 / SYNDIG1 C12orf70 / Liprin-beta-1 isoform 4 <br> C11orf96 / ACCSL | Cytohesin 1 | $\begin{array}{\|l\|} \hline 12 \mathrm{p} 13 \\ 12 \mathrm{p} 13 \\ 17 \mathrm{q} 25 \\ 20 \mathrm{p} 11 \\ 12 \mathrm{p} 12 \\ 11 \mathrm{p} 11.2 \\ \hline \end{array}$ |
|  | NLS2 | $\begin{array}{\|l\|} \hline \text { 1B6 } \\ \text { 1C4 } \\ \text { 1D1 } \\ \hline \end{array}$ | MYCN/FAM49A <br> Proline-rich protein 16 / Ferritin mitochondrial | Topoisomerase (DNA) II alpha 170kDa | $\begin{array}{\|l\|} \hline 2 q 24.2 \\ 5 q 23.1 \\ 17 q 21 \\ \hline \end{array}$ |
|  | NLS3 | $\begin{aligned} & \hline \text { 1D1 } \\ & \text { 2A5 } \\ & \text { 2C1 } \\ & \hline \end{aligned}$ | Myc proto-oncogene protein / Gasdermin-C | Nuclear receptor interacting protein 1 CDC28 protein kinase regulatory subunit 1B | $\begin{array}{\|l\|} \hline 21 q 11.2 \\ 1 q 21.2 \\ 8 q 24.2 \\ \hline \end{array}$ |
|  | MEM1 | $\begin{array}{\|l} \hline 1 \mathrm{~A} 3 \\ 1 \mathrm{~A} 5 \\ 1 \mathrm{~A} 6 \\ 1 \mathrm{~B} 2 \\ \text { 2D6 } \\ \hline \end{array}$ | C1orf229 / Zinc finger protein 124 | Slingshot homolog 2 <br> Cryptochrome 1 <br> ELOVL fatty acid elongase 5 <br> Keratin 1 | $1 q 44$ <br> $17 q 11.2$ <br> $12 q 23$ <br> $6 p 21.1$ <br> $12 q 13.13$ |
|  | MEM2 | $\begin{array}{\|l\|} \hline \text { 1C6 } \\ \text { 1D1 } \\ \text { 1D5 } \\ \hline \end{array}$ |  | MOB kinase activator 3A <br> Solute carrier family 43 , member 2 Hexamethylene bis-acetamide inducible 1 | $\begin{array}{\|l\|} \hline 19 p 13.3 \\ 17 \mathrm{p} 13.3 \\ 17 \mathrm{q} 21.31 \\ \hline \end{array}$ |
|  | MEM3 | $\begin{aligned} & 1 \mathrm{~A} 2 \\ & 1 \mathrm{~B} 3 \\ & 1 \mathrm{~B} 4 \\ & 1 \mathrm{~B} 5 \\ & 1 \mathrm{C} 1 \\ & 1 \mathrm{C} 2 \\ & 1 \mathrm{C} 6 \\ & \hline \end{aligned}$ | FYN binding protein / Complement component 9 FYN binding protein / Complement component 9 | Defensin, beta 4A <br> FERM domain containing 4B <br> FYN binding protein <br> FYN binding protein <br> FYN binding protein | 8p23.1 <br> 3p14.1 <br> 5p13.1 <br> 5p13.1 <br> 5p13.1 <br> 5p13.1 <br> 5p13.1 |

[^0]| Gene Symbol | EntrezGene ID | ProbeName | GenbankAccession | Description | FCAbsolute | $p$-value | logFC RNA |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Histones |  |  |  |  |  |  |  |
| H1FX | 8971 | A_23_P96087 | NM_006026 | H1 histone family, member X (H1FX), mRNA [NM_006026] | 3.87687 | 0.0047091 | 0.003404416 |
| H2AFJ | 55766 | A_24_P236003 | NM_177925 | H2A histone family, member J (H2AFJ), transcript variant 2, mRNA [NM_177925] | 4.7487535 | 0.002603759 | 78236 |
| нзғ3в | 3021 | A_23_P152516 | NM_005324 | H3 histone, family 3B (H3.3B) (H3F3B), mRNA [NM_005324] | 3.7573144 | 5.21E-05 | 0.092142511 |
| HIST1H1C | 3006 | A_23_P122443 | NM_005319 | histone cluster 1, H1c (HIST1H1C), mRNA [NM_005319] | 6.4905505 | 0.00348125 | 0.3 |
| HIST1H1D | 3007 | A_24_P260639 | NM_005320 | histone cluster 1, H1d (HIST1H1D), mRNA [NM_005320] | 4.631392 | 0.003491658 | 0.27904298 |
| HIST1H2AB | 8335 | A_24_P223384 | NM_003513 | histone cluster 1, H2ab (HIST1H2AB), mRNA [NM_003513] | 5.941576 | 016 | 0.307751065 |
| HIST1H2AC | 8334 | A_23_P372860 | NM_003512 | histone cluster 1, H2ac (HIST1H2AC), mRNA [NM_003512] | 9.26241 | 0.005724356 | 0.084224222 |
| HIST1H2AD | 3013 | A_23_P428184 | NM_021065 | histone cluster 1, H2ad (HIST1H2AD), mRNA [NM_021065] | 6.2743306 | 0.001889621 | -0.103736596 |
| HIST1H2AE | 2 | A_23_P59045 | NM_021052 | histone cluster 1, H2ae (HIST1H2AE), mRNA [NM_021052] | 4.3202634 | 0.005601537 | -0.017556739 |
| HIST1H2AH | 85235 | A_23_P81859 | NM_080596 | histone cluster 1, H2ah (HIST1H2AH), mRNA [NM_080596] | 5.948902 | 0.007667313 | 0.475197631 |
| HIST1H2AK |  | A_24_P217848 | NM_003510 | histone cluster 1, H2ak (HIST1H2AK), mRNA [NM_003510] | 7.610374 | 0.003799502 | -0.012348964 |
| HIST1H2AM | 8336 | A_24_P86389 | NM_003514 | histone cluster 1, H2am (HIST1H2AM), mRNA [NM_003514] | 5.9595294 | 0.008196656 | 0.338437496 |
| HIST1H2BD | 3017 | A_24_P146211 | NM_021063 | histone cluster 1, H2bd (HIST1H2BD), transcript variant 1, mRNA [NM_021063] | 4.247539 | 0.011999182 | 0.019796474 |
| HIST1H2BE | 8344 | A_23_P40470 | NM_003523 | histone cluster 1, H2be (HIST1H2BE), mRNA [NM_003523] | 4.2729325 | 0.002672735 | 0.302068077 |
| HIST1H2BG | 339 | A_23_P167997 | NM_003518 | histone cluster 1, H2bg (HIST1H2BG), mRNA [NM_003518] | 4.501325 | 0.007847901 | -0.257993148 |
| HIST1H2BI | 8346 | A_23_P111041 | NM_003525 | histone cluster 1, H2bi (HIST1H2BI), mRNA [NM_003525] | 3.9637601 | 0.003272965 | $-0.383257748$ |
| HIST1H2BL | 8340 | A_23_P8013 | NM_003519 | histone cluster 1, H2bl (HIST1H2BL), mRNA [NM_003519] | 4.291472 | 0.009281887 | 0.044985383 |
| HIST1H2BM | 8342 | A_24_P3783 | NM_003521 | histone cluster 1, H2bm (HIST1H2BM), mRNA [NM_003521] | 3.988967 | 0.002465271 | -0.275218894 |
| HIST1H2BN | 8341 | A_23_P402081 | NM_003520 | histone cluster 1, H2bn (HIST1H2BN), mRNA [NM_003520] | 4.3840466 | 0.010517041 | -0.065151793 |
| HIST1H3B | 8358 | A_24_P174924 | NM_003537 | histone cluster 1, H3b (HIST1H3B), mRNA [NM_003537] | 9.451302 | 0.003595352 | -0.148710017 |
| HIST1H3C | 8352 | A_23_P133814 | NM_003531 | histone cluster 1, H3c (HIST1H3C), mRNA [NM_003531] | 4.7221613 | 0.004147666 | 0.06954691 |
| HIST1H3D | 8351 | A_24_P217834 | NM_003530 | histone cluster 1, H3d (HIST1H3D), mRNA [NM_003530] | 9.012119 | 0.008122187 | 0.127656124 |
| HIST1H3G | 8355 | A_23_P42198 | NM_003534 | histone cluster 1, H3g (HIST1H3G), mRNA [NM_003534] | 6.084677 | 0.011490446 | 0.172193562 |
| HIST1H31 | 8354 | A_24_P9321 | NM_003533 | histone cluster 1, H3i (HIST1H31), mRNA [NM_003533] | 4.908716 | 0.001970914 | 0.115697593 |
| HIST2H2AA3 | 8337 | A_23_P309381 | NM_003516 | histone cluster 2, H2aa3 (HIST2H2AA3), mRNA [NM_003516] | 7.234894 | 0.001999636 | 0.156047113 |
| HIST2H2AB | 317772 | A_24_P68631 | NM_175065 | histone cluster 2, H2ab (HIST2H2AB), mRNA [NM_175065] | 5.14886 | 0.009893297 | -0.230590403 |
| HIST2H2AC | 8338 | A_24_P8721 | NM_003517 | histone cluster 2, H2ac (HIST2H2AC), mRNA [NM_003517] | 8.251695 | 0.004336114 | $-0.332275715$ |
| HIST2H2BE | 8349 | A_24_P156911 | NM_003528 | histone cluster 2, H2be (HIST2H2BE), mRNA [NM_003528] | 4.568563 | 0.010834846 | $-0.163684688$ |
| HIST2H3A | 333932 | A_23_P115375 | NM_001005464 | histone cluster 2, H3a (HIST2H3A), mRNA [NM_001005464] | 13.457071 | 0.003003158 | N.I. |
| HIST3H2A | 2815 | A_23_P149301 | NM_033445 | histone cluster 3, H2a (HIST3H2A), mRNA [NM_033445] | 6.1659255 | 0.009170881 | -0.139142341 |
| HIST3H2BB | 128312 | A_23_P332992 | NM_175055 | histone cluster 3, H2bb (HIST3H2BB), mRNA [NM_175055] | 4.0308 | 0.003272943 | 0.943382169 |
| HIST3H3 | 8290 | A_23_P137909 | NM_003493 | histone cluster 3, H3 (HIST3H3), mRNA [NM_003493] | 7.293737 | $2.98 \mathrm{E}-04$ | -0.882899372 |
| HIST4H4 | 121504 | A_23_P388871 | NM_175054 | histone cluster 4, H4 (HIST4H4), mRNA [NM_175054] | 12.452248 | $8.03 \mathrm{E}-04$ |  |
| LOC440093 | 440093 | A_32_P12214 | NM_001013699 | similar to H3 histone, family 3B (LOC440093), mRNA [NM_001013699] | 4.569646 | 1.84E-06 | 0.05925017 |
| Mitochondrial Proteins |  |  |  |  |  |  |  |
| AFG3L2 | 10939 | A_32_P117338 | NM_006796 | AFG3 ATPase family gene 3 -like 2 (yeast) (AFG3L2), mRNA [ NM _006796] | 3.7661774 | 0.00134532 | 0.925972262 |
| C12orf65 | 91574 | A_23_P339003 | NM_152269 | chromosome 12 open reading frame 65 (C12orf65), mRNA [NM_152269] | 3.9480476 | 3.13E-04 | -0.037543333 |
| CHCHD3 | 54927 | A_32_P159150 | NM_017812 | coiled-coil-helix-coiled-coil-helix domain containing 3 (CHCHD3), mRNA [NM_017812] | 3.5508165 | 0.012479872 | -0.044155526 |
| COQ4 | 51117 | A_24_P389491 | NM_016035 | coenzyme Q4 homolog (S. cerevisiae) (COQ4), mRNA [NM_016035] | 3.7592945 | 2.66E-04 | 0.150944543 |
| CYB5B | 80777 | A_23_P206697 | NM_030579 | cytochrome b5 type B (outer mitochondrial membrane) (CYB5B), mRNA [NM_030579] | 4.4442697 | 0.002271432 | -0.009484903 |
| DHRS4 | 10901 | A_23_P162982 | NM_021004 | dehydrogenase/reductase (SDR family) member 4 (DHRS4), mRNA [NM_021004] | 3.7148697 | 0.002045734 | 0.13558824 |
| ECH1 | 1891 | A_23_P153853 | NM_001398 | enoyl Coenzyme A hydratase 1, peroxisomal (ECH1), mRNA [NM_001398] | 4.5474977 | 0.00141372 | 0.179311318 |
| ENDOGL1 | 9941 | A_24_P24444 | NM_005107 | endonuclease G-like 1 (ENDOGL1), mRNA [ ${ }^{\text {a M }}$-005107] | 5.0326395 | 0.004892046 | 0.018150387 |
| ERAL1 | 26284 | A_23_P71981 | NM_005702 | Era G-protein-like 1 (E. coli) (ERAL1), mRNA [NM_005702] | 3.5932307 | 7.37E-04 | 0.002852379 |
| GRPEL1 | 80273 | A_24_P174563 | NM_025196 | Grpe-like 1, mitochondrial (E. coli) (GRPEL1), mRNA [NM_025196] | 4.5121446 | 2.95E-04 | 0.306687816 |
| MLYCD | 23417 | A_23_P88817 | NM_012213 | malonyl-CoA decarboxylase (MLYCD), mRNA [NM_012213] | 7.3015447 | 0.002779396 | -0.288203997 |
| MRPL3 | 11222 | A_23_P7030 | NM_007208 | mitochondrial ribosomal protein L3 (MRPL3), mRNA [NM_007208] | 5.576191 | 0.003042849 | 0.210408669 |
| MRPL38 | 64978 | A_23_P54963 | NM_032478 | mitochondrial ribosomal protein L38 (MRPL38), mRNA [NM_032478] | 3.774992 | 0.003000696 | -0.024578551 |
| MRPL49 | 740 | A_23_P138819 | NM_004927 | mitochondrial ribosomal protein L49 (MRPL49), mRNA [NM_004927] | 5.9330945 | 3.67E-04 | 0.241870942 |
| MRPS11 | 64963 | A_24_P935318 | NM_022839 | mitochondrial ribosomal protein S11 (MRPS11), mRNA [NM_022839] | 3.7820513 | 0.007972163 | $-0.052741851$ |
| NDUFS5 | 4725 | A_23_P10463 | NM_004552 | NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa, mRNA [NM_004552] | 5.196022 | 1.76E-04 | -0.094677741 |
| PDI | 5165 | A_23_P250478 | NM_005391 | pyruvate dehydrogenase kinase, isozyme 3 (PDK3), mRNA [ ${ }^{\text {a M _005391] }}$ | 4.045194 | 8.71E-04 | 0.244788039 |
| PECR | 5582 | A_23_P91140 | NM_018441 | peroxisomal trans-2-enoyl-CoA reductase (PECR), mRNA [NM_018441] | 3.5095732 | 1.20E-04 | -0.127270831 |
| SDHC | 6391 | A_24_P233850 | NM_003001 | succinate dehydrogenase complex, subunit C, 15kDa (SDHC), mRNA [NM_003001] | 3.9940686 | 0.001516132 | -0.237860906 |
| SH3BP5 | 9467 | A_24_P148750 | NM_004844 | SH3-domain binding protein 5 (BTK-associated) (SH3BP5),mRNA [NM_004844] | 4.2188463 | 0.003000793 | 0.42225273 |


| SBP1 | 6742 | A_23_P31536 | \|NM_003143 | single-stranded DNA binding protein 1 (SSBP1), mRNA [NM_003143] | 3.5105083 | 3.05E-04 | -0.331059187 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| TFAM | 19 | A_24_P134727 | NM_003201 | transcription factor A, mitochondrial (TFAM), mRNA [NM_003201] | 3.647071 | 51E-0 | -0.157639354 |
| томм 34 | 10953 | A_23_P57033 | NM_006809 | translocase of outer mitochondrial membrane 34 (TOMM34), mRNA [NM_006809] | 6.9714594 | 3.74E-04 | . 33241783 |
| Mm40 | 10452 | A_24_P178093 | NM_006114 | translocase of outer mitochondrial membrane 40 homolog, mRNA [NM_006114] | 4.6797104 | 0.004695755 | 186 |
| TTC19 | 02 | A_24_P126393 | NM_017775 | tetratricopeptide repeat domain 19 (TC19), mRNA [NM_017775] | 4.35522 | 0.002828887 | -0.050970013 |
| Vesicular Transport |  |  |  |  |  |  |  |
| AP2M1 | 1173 | A_23_P155624 | NM_004068 | adaptor-related protein complex 2, mu 1 subunit (AP2M1), mRNA [NM_004068] | 3.5457442 | 0.01031662 | -0.100125098 |
| ARF | 377 | A_23_P36521 | NM_001659 | ADP-ribosylation factor 3 (ARF3), mRNA [NM_001659] | 4.039595 | 2.22 | . 092200104 |
| ATP6V1D | 51382 | A_23_P140115 | NM_015994 | ATPase, $\mathrm{H}+$ transporting, lysosomal 34kDa, V1 subunit D (ATP6V1D), mRNA [NM_015994] | 3.6205635 | $5.20 \mathrm{E}-05$ | -0.1 |
| CHMP7 | 91782 | A_32_P70220 | NM_152272 | CHMP family, member 7 (CHMP7), mRNA [NM_152272] | 36 | $5.32 \mathrm{E}-04$ | 0.2 |
| COPE | 11316 | A_24_P399622 | NM_199444 | coatomer protein complex, subunit epsilon (COPE), transcript variant 3, mRNA [NM_199444] | 5.664686 | 3.12E-04 | 0.056479237 |
| DENND1B | 163486 | A_23_P201605 | NM_144977 | DENN/MADD domain containing 1B (DENND1B), mRNA [NM_144977] | 4.927893 | 5.23E-04 | 0.585976807 |
| GOLGA3 | 2802 | A_23_P98864 | NM_005895 | golgi autoantigen, golgin subfamily a, 3 (GOLGA3), mRNA [NM_005895] | 4.899892 | 0.001383066 | -0.07094354 |
| GOLPH2 | 51280 | A_24_P394865 | NM_016548 | golgi phosphoprotein 2 (GOLPH2), transcript variant 1, mRNA [NM_016548] | 4.9918213 | 8.62E-04 | 0.051037511 |
| GORASP2 | 26003 | A_24_P328320 | NM_015530 | golgi reassembly stacking protein $2,55 \mathrm{kDa}$ (GORASP2), mRNA [NM_015530] | 4.6763873 | 2.44-04 | 0.371436299 |
| LAPTM4B | 55353 | A_24_P414999 | NM_018407 | Iysosomal associated protein transmembrane 4 beta (LAPTM4B), mRNA [NM_018407] | 4.750426 | 0.001584326 | -0.228927305 |
| NAP | 8775 | A_23_P55990 | NM_003827 | N-ethylmaleimide-sensitive factor attachment protein, alpha (NAPA), mRNA [NM_003827] | 5.545775 | 4.41E-04 | 0.126750582 |
| RAB1B | 876 | A_23_P64090 | NM_030981 | RAB1B, member RAS oncogene family (RAB1B), mRNA [NM_030981] | 7.8021164 | . 07477358 | -0.750527084 |
| RAB21 | 1 | A_24_P247749 | NM_014999 | RAB21, member RAS oncogene family (RAB21), mRNA [NM_014999] | 7.293949 | 0.002303502 | 0.295678876 |
| RAB5C | 5878 | A_23_P107211 | NM_201434 | RAB5C, member RAS oncogene family (RAB5C), transcript variant 1, mRNA [NM_201434] | 4.1075897 | 0.001544687 | 0.146006932 |
| RAB7A | 789 | A_24_P234572 | NM_004637 | RAB7A, member RAS oncogene family (RAB7A), mRNA [NM_004637] | 5.5856795 | $5.86 \mathrm{E}-04$ | -0.069336447 |
| SCAMP2 | 0066 | A_23_P385081 | NM_005697 | secretory carrier membrane protein 2 (SCAMP2), mRNA [NM_005697] | 3.9955194 | $5.63 \mathrm{E}-04$ | -0.18358624 |
| SCAMP3 | 0067 | A_23_P97274 | NM_052837 | secretory carrier membrane protein 3 (SCAMP3), transcript variant 2, mRNA [NM_052837] | 3.5104465 | 2.30E-04 | 0.122917478 |
| SFT2D2 | 375035 | A_23_P148785 | NM_199344 | SFT2 domain containing 2 (SFT2D2), mRNA [NM_199344] | 3.840829 | 05326902 | -0.126058272 |
| SNX17 | 9784 | A_23_P28238 | NM_014748 | sorting nexin 17 (SNX17), mRNA [NM_014748] | 549111 | 0.012332906 | -0.191836146 |
| STX18 | 3407 | A_24_P388622 | NM_016930 | syntaxin 18 (STX18), mRNA [NM_016930] | 3.641451 | 7.37E-04 | -0.274393366 |
| TRAPPC6A | 7909 | A_24_P390928 | NM_024108 | trafficking protein particle complex 6A (TRAPPC6A), mRNA [NM_024108] | 3.7415912 | 3.54E-05 | 0.587678106 |
| VAPA | 9218 | A_23_P382199 | NM_003574 | VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa, mRNA [NM_003574] | 3.5910416 | 0.002880531 | -0.148040567 |
| vPS39 | 23339 | A_23_P100103 | NM_015289 | vacuolar protein sorting 39 homolog (S. cerevisiae) (VPS39), mRNA [NM_015289] | 4489408 | 0.006613969 | 0.770155558 |
| Cell Cycle |  |  |  |  |  |  |  |
| CBX5 | 23468 | A_23_P2355 | NM_012117 | chromobox homolog 5 (HP1 alpha homolog, Drosophila) (CBX5), mRNA [NM_012117] | 4.150486 | 2.95E-05 | -0.033699817 |
| CDK6 | 1 | A_23_P168651 | NM_001259 | cyclin-dependent kinase 6 (CDK6), mRNA [NM_001259] | 7.8250427 | 0.001233212 | -0.002011879 |
| MAPK1 | 94 | A_23_P257895 | NM_138957 | mitogen-activated protein kinase 1 (MAPK1), transcript variant 2, mRNA [NM_138957] | 3.5353088 | 2.61E-04 | $-0.247222475$ |
| MAPK14 | 1432 | A_24_P397566 | NM_139013 | mitogen-activated protein kinase 14 (MAPK14), transcript variant 3, mRNA [NM_139013] | 3.903526 | 0.002112991 | -0.203185847 |
| PTMA | 5757 | A_24_P264207 | NM_002823 | prothymosin, alpha (gene sequence 28) (PTMA), mRNA [NM_002823] | 10.714185 | 3.79E-04 | $-0.251064844$ |
| Ran | 5901 | A_32_P506600 | NM_006325 | RAN, member RAS oncogene family (RAN), mRNA [NM_006325] | 4.397727 | 1.53E-04 | -0.092000636 |
| RHOA | 387 | A_24_P174550 | NM_001664 | ras homolog gene family, member A (RHOA), mRNA [NM_001664] | 5.449942 | 0.002297695 | 0.103015448 |
| RUVBL1 | 8607 | A_32_P30693 | NM_003707 | RuvB-like 1 (E. coli) (RUVBL1), mRNA [NM_003707] | 3.947765 | 0.009505489 | 0.106850576 |
| SCAND1 | 51282 | A_23_P6196 | NM_016558 | SCAN domain containing 1 (SCAND1), transcript variant 1, mRNA [NM_016558] | 3.852981 | 4.39E-04 | 0.003989829 |
| SEPT2 | 4735 | A_24_P43092 | NM_001008491 | septin 2 (SEPT2), transcript variant 1, mRNA [NM_001008491] | 4.463853 | 0.00208986 | 0.271663537 |
| SMEK1 | 55671 | A_24_P369691 | NM_032560 | SMEK homolog 1, suppressor of mek1 (Dictyostelium) (SMEK1), mRNA [NM_032560] | 3.9156673 | 0.002503073 | $-0.213158833$ |
| STK4 | 6789 | A_23_P143199 | NM_006282 | serine/threonine kinase 4 (STK4), mRNA [NM_006282] | 3.5498006 | 7.61E-04 | $-0.240837343$ |
| TIMELESS | 8914 | A_24_P231004 | NM_003920 | timeless homolog (Drosophila) (TIMELESS), mRNA [NM_003920] | 4.95406 | 0.002980027 | 0.325204334 |
| YWHAB | 7529 | A_23_P500251 | NM_003404 | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta polypeptide, mRNA [NM_003404] | 3.8492427 | 4.76E-05 | 0.124945406 |
| Transcription |  |  |  |  |  |  |  |
| AFF4 | 27125 | A_24_P394408 | NM_014423 | AF4/FMR2 family, member 4 (AFF4), mRNA [NM_014423] | 5.251953 | 0.002908462 | $-0.275774495$ |
| LCOR | 444 | A_23_P328836 | NM_032440 | ligand dependent nuclear receptor corepressor (LCOR), mRNA [NM_032440] | 3.5043979 | 0.0040297 | -0.08703071 |
| MGC29891 | 126626 | A_24_P191207 | NM_144618 | hypothetical protein MGC29891 (MGC29891), mRNA [NM_144618] | 4.77659 | 0.001411601 | 0.15723534 |
| NR1H2 | 7376 | A_23_P55926 | NM_007121 | nuclear receptor subfamily 1, group H, member 2 (NR1H2), mRNA [NM_007121] | 3.866714 | 0.001633707 | 0.024037451 |
| NXN | 64359 | A_23_P61778 | NM_022463 | nucleoredoxin (NXN), mRNA [NM_022463] | 4.837317 | 7.17E-04 | 0.438540439 |
| REXO4 | 5710 | A_23_P157861 | NM_020385 | REX4, RNA exonuclease 4 homolog (S. cerevisiae) (REXO4), mRNA [NM_020385] | 4.2764845 | 7.08E-04 | 0.136332191 |
| SCYI | 57410 | A_23_P75470 | NM_020680 | SCY1-like 1 (S. cerevisiae) (SCYL1), transcript variant A, mRNA [NM_020680] | 3.5090451 | 0.004178692 | 0.070811768 |
| SETD7 | 80854 | A_23_P80966 | NM_030648 | SET domain containing (lysine methyltransferase) 7 (SETD7), mRNA [NM_030648] | 8.036785 | 0.011688318 | -0.231608287 |
| SMARCD1 | 6602 | A_23_P204745 | NM_139071 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily d, mRNA [NM_139071] | 4.0041122 | 0.007162517 | -0.159161725 |
| SSBP3 | 236 | A_24_P375453 | NM_001009955 | single stranded DNA binding protein 3 (SSBP3), transcript variant 3, mRNA [NM_001009955] | 3.734599 | 0.011738982 | -0.280069375 |
| TMEM113 | 80335 | A_24_P388536 | NM_025222 | transmembrane protein 113 (TMEM113), mRNA [NM_025222] | 3.783626 | 0.005087834 | $-0.187407351$ |
| ZXDC | 80292 | A_24_P922397 |  | ZXD family zinc finger C (ZXDC), transcript variant 2, mRNA [NM_001040653] Agilent | 4.018627 | 1.49E-04 | -0.198037002 |
| Cytosckeleton Organization |  |  |  |  |  |  |  |
| AAMP |  | A_23_P56529 | \|NM_001087 | angio-associated, migratory cell protein (AAMP), mRNA [NM_001087] | 3.6952455 | 0.001701752 | -0.497122693 |


| \|ARHGDIB | 397 | A_23_P151075 | NM_001175 | Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB), mRNA [NM_001175] | 6.1358 | 5.05E-05 | -0.156837872 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ARPC4 | 10093 | A_23_P29566 | NM_005718 | actin related protein $2 / 3$ complex, subunit 4, 20kDa (ARPC4), transcript variant 1, mRNA [NM_005718] | 5.1617007 | 0.001829339 | 0.00080338 |
| C6orf206 | 221421 | A_24_P52189 | AK055407 | cDNA FU30845 fis, clone FEBRA2002727. [AK055407] | 6.330771 | 0.003550302 | -0.130088224 |
| MAPRE2 | 0982 | A_24_P193911 | NM_014268 | microtubule-associated protein, RP/EB family, member 2 (MAPRE2), mRNA [NM_014268] | 8.343991 | 5.92E-04 | -0.129261351 |
| MYL6 | 4637 | A_23_P344973 | NM_079423 | myosin, light chain 6, alkali, smooth muscle and non-muscle (MYL6), transcript variant 2, mRNA [NM_079423] | 3.6509323 | $1.55 \mathrm{E}-04$ | -0.038605236 |
| муо9в | 4650 | A_24_P922921 | NM_004145 | myosin IXB (MYO9B), mRNA [NM_004145] | 5.3462934 | 4.27E-04 | -0.165941073 |
| PDPK1 | 5170 | A_24_P830690 | NM_002613 | 3 -phosphoinositide dependent protein kinase-1 (PDPK1), transcript variant 1, mRNA [NM_002613] | 5.129891 | 1.32E-04 | -0.367326597 |
| PIP5K1A | 8394 | A_23_P23572 | NM_003557 | phosphatidylinositol-4-phosphate 5 -kinase, type I, alpha (PIP5K1A), mRNA [NM_003557] | 4.061195 | 0.007036914 | -0.094774677 |
| TRIO | 7204 | A_24_P42603 | NM_007118 | triple functional domain (PTPRF interacting) (TRIO), mRNA [NM_007118] | 3.5016432 | 0.001180741 | 108991931 |
| TUBGCP2 | 10844 | A_23_P127150 | NM_006659 | tubulin, gamma complex associated protein 2 (TUBGCP2), mRNA [NM_006659] | 3.7539735 | $2.49 \mathrm{E}-04$ | 0.127277631 |
| RNA Processing |  |  |  |  |  |  |  |
| ADAT1 | 23536 | A_24_P48139 | NM_012091 | adenosine deaminase, tRNA-specific 1 (ADAT1), mRNA [NM_012091] | 3.633133 | 0.00853758 | -0.022681704 |
| DCP2 | 167227 | A_23_P256868 | NM_152624 | DCP2 decapping enzyme homolog (S. cerevisiae) (DCP2), mRNA [NM_152624] | 4.8735456 | $6.77 \mathrm{E}-04$ | -0.121276001 |
| EXOSC5 | 56915 | A_24_P211151 | NM_020158 | exosome component 5 (EXOSC5), mRNA [NM_020158] | . 06311 | 04 | - 18149941 |
| HNRPAB | 3182 | A_23_P19084 | NM_004499 | heterogeneous nuclear ribonucleoprotein A/B (HNRPAB), transcript variant 2, mRNA [NM_004499] | 5.0968943 | 0.002330112 | N.I. |
| RNPS1 | 21 | A_24_P725630 | NM_006711 | RNA binding protein S1, serine-rich domain (RNPS1), transcript variant 1, mRNA [NM_006711] | 3.7806795 | 0.008888845 | 0.360513499 |
| RPUSD3 | 285367 | A_23_P255916 | NM_173659 | RNA pseudouridylate synthase domain containing 3 (RPUSD3), mRNA [NM_173659] | 3.5483909 | 5.25E-04 | 0.299408828 |
| SNRP | 6628 | A_23_P154675 | NM_198216 | small nuclear ribonucleoprotein polypeptides B and B1 (SNRPB), transcript variant 1, mRNA [NM_198216] | 3.792452 | 0.005617595 | 0.35746232 |
| TNRC | 23112 | A_24_P786172 | NM_015088 | trinucleotide repeat containing 6B (TNRC6B), transcript variant 1, mRNA [NM_015088] | 3.6123264 | 0.006184844 | 0.011847781 |
| TSR2 | 121 | A_23_P414269 | NM_058163 | TSR2, 20S rRNA accumulation, homolog (S. cerevisiae) (TSR2), mRNA [NM_058163] | 3.9734452 | 0.001964119 | -0.143831849 |
| DR55 | 5485 | A_24_P200549 | NM_017706 | WD repeat domain 55 (WDR55), mRNA [NM_017706] | 4.4930825 | 0.001128758 | $-0.261034191$ |
| ZMATS | 55954 | A_23_P132248 | NM_019103 | zinc finger, matrin type 5 (ZMAT5), transcript variant 1, mRNA [NM_019103] | 6.9478564 | 7.52E-04 | $-0.392138986$ |
| Tumorigenesis |  |  |  |  |  |  |  |
| ABL1 | 25 | A_24_P393711 | NM_005157 | v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), transcript variant a, mRNA [NM_005157] | 4.5879054 | 9.47E-04 | 9.47E-04 |
| ANP32A | 8125 | A_32_P133670 | NM_006305 | acidic (leucine-rich) nuclear phosphoprotein 32 family, member A (ANP32A), mRNA [NM_006305] | 61744 | 0.010472801 | 0.010472801 |
| ANP32C | 23520 | A_23_P92520 | NM_012403 | acidic (leucine-rich) nuclear phosphoprotein 32 family, member C (ANP32C), mRNA [NM_012403] | 6.3007956 | 0.005655 | 0.005655026 |
| C6orf173 | 387103 | A_32_P143245 | NM_001012507 | chromosome 6 open reading frame 173 (C6orf173), mRNA [NM_001012507] | 5.9531865 | 71E-05 | 5 |
| ENOX2 | 10495 | A_24_P391468 | NM_182314 | cytosolic ovarian carcinoma antigen 1 (COVA1), transcript variant 2, mRNA [NM_182314] | 3.8306012 | 01708381 | 01708381 |
| PPP1CA | 5499 | A_23_P434710 | NM_001008709 | protein phosphatase 1, catalytic subunit, alpha isoform (PPP1CA), transcript variant 3, mRNA [NM_001008709] | . 696 | 0.00333480 | 0.098455499 |
| PTOV1 | 53635 | A_23_P325080 | NM_017432 | prostate tumor overexpressed gene 1 (PTOV1), mRNA [NM_017432] | 4.7075696 | 4.43 | -0.21950973 |
| RAB8A | 4218 | A_23_P164752 | NM_005370 | RAB8A, member RAS oncogene family (RAB8A), mRNA [NM_005370] | 4.5002646 | 0.00229918 | -0.267841813 |
| SELENBP1 | 8991 | A_23_P74619 | NM_003944 | selenium binding protein 1 (SELENBP1), mRNA [NM_003944] | . 007956 | 5.61E-04 | 0.319437728 |
| SKI | 6497 | A_24_P338603 | NM_003036 | V-ski sarcoma viral oncogene homolog (avian) (SK1), mRNA [NM_003036] | 5.084857 | 0.008819896 | 0.407098105 |
| Development |  |  |  |  |  |  |  |
| CVR2B | 93 | A_23_P109950 | NM_001106 | activin A receptor, type IIB (ACVR2B), mRNA [NM_001106] | 5561876 | 4.69E-04 | 4.69E-04 |
| ADAMTS7 | 173 | A_23_P37624 | AF140675 | zinc metalloprotease ADAMTS7 (ADAMTS7) mRNA, complete cds. [AF140675] | 3.8011234 | 0.001162121 | 0.001162121 |
| BBS5 | 2988 | A_23_P5785 | NM_152384 | Bardet-Biedl syndrome 5 (BBS5), mRNA [NM_152384] | 4.0974236 | 0.007936392 | 0.007936392 |
| CREBB | 1387 | A_24_P342279 | NM_004380 | CREB binding protein (Rubinstein-Taybi syndrome) (CREBBP), transcript variant 1, mRNA [NM_004380] | 4.289346 | 0.008835916 | 0.008835916 |
| FGFR1 | 2260 | A_24_P4171 | NM_023111 | fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome), mRNA [NM_023111] | 5.3067718 | 0.011039325 | 0.011039325 |
| H0XA10 | 3206 | A_24_P914411 | S69027 | HOX C6=class I homeodomain \{fragment M13, homeodomain\} [S69027] | 3.803851 | 0.007220427 |  |
| TAOK1 | 57551 | A_23_P38457 | NM_020791 | TAO kinase 1 (TAOK1), mRNA [NM_020791] | 4.648342 | 3.21E-04 | 0.096721255 |
| THRAP2 | 23389 | A_24_P911508 | NM_015335 | thyroid hormone receptor associated protein 2 (THRAP2), mRNA [NM_015335] | 5.411525 | 0.003208764 | -0.001601489 |
| TRIM44 | 54765 | A_24_P192821 | NM_017583 | tripartite motif-containing 44 (TRIM44), mRNA [NM_017583] | 3.55853 | 3.02E-04 | -0.072582369 |
| Apoptosis |  |  |  |  |  |  |  |
| BOK | 666 | A_23_P61112 | AF089746 | Bcl-2 related ovarian killer (BOK) mRNA, complete cds. [AF089746] | 3.7052493 | 0.00432121 | 0.00432121 |
| C1D | 10438 | A_23_P56590 | NM_006333 | nuclear DNA-binding protein (C1D), transcript variant 1, mRNA [NM_006333] | 3.5132194 | 1.311-04 | 1.311-04 |
| DAD1 | 1603 | A_23_P106056 | NM_001344 | defender against cell death 1 (DAD1), mRNA [NM_001344] | 3.635886 | 3.32E-04 | 3.32E-04 |
| DFFB | 677 | A_24_P370626 | NM_001004285 | DNA fragmentation factor, 40kDa, beta polypeptide (caspase-activated DNase), mRNA [NM_001004285] | 5.925662 | 0.003967213 | 0.003967213 |
| FAM82C | 55177 | A_24_P296280 | NM_018145 | family with sequence similarity 82, member C (FAM82C), mRNA [NM_018145] | 4.3146267 | 0.005278487 | 0.005278487 |
| MAP2K6 | 5608 | A_24_P416489 |  | Dual specificity mitogen-activated protein kinase kinase 6 (EC 2.7.12.2) (MAP kinase kinase 6) [ENST00000359094] | 5.6349616 | 0.004105873 | -0.293578389 |
| MAP4K4 | 9448 | A_23_P102192 | NM_145686 | mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), transcript variant 2, mRNA [NM_145686] | 3.610419 | 0.008489762 | $-0.173558829$ |
| PDCL3 | 79031 | A_32_P157531 | NM_024065 | phosducin-like 3 (PDCL3), mRNA [NM_024065] | 3.736076 | 0.002133665 | $-0.067209927$ |
| Protein Degradation |  |  |  |  |  |  |  |
| FBX036 | 130888 | A_24_P254702 | NM_174899 | F-box protein 36 (FBXO36), mRNA [NM_174899] | 3.8612113 | 7.82E-04 | 7.82E-04 |
| HERC2 | 8924 | A_23_P48973 | NM_004667 | hect domain and RLD 2 (HERC2), mRNA [NM_004667] | 6.202575 | 0.003272481 | 0.003272481 |
| HUWE1 | 10075 | A_24_P932016 | NM_031407 | HECT, UBA and WWE domain containing 1 (HUWE1), mRNA [NM_031407] | 3.765481 | 0.001565655 | 0.647979861 |
| PSMD13 | 5719 | A_23_P75889 | NM_175932 | proteasome (prosome, macropain) 265 subunit, non-ATPase, 13 (PSMD13), transcript variant 2, mRNA [NM_175932] | 4.1500163 | 0.003752919 | -0.125131845 |
| PSME3 | 10197 | A_24_P352864 | NM_005789 | proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki), transcript variant 1, mRNA [NM_005789] | 3.8185866 | 7.01E-04 | 0.210002213 |
| SERPINB8 | 5271 | A_24_P147461 | NM_198833 | serpin peptidase inhibitor, clade B (ovalbumin), member 8 (SERPINB8), transcript variant 2, mRNA [NM_198833] | 4.107185 | $8.53 \mathrm{E}-04$ | -0.190785216 |


| UBE2NL | 389898 | A_23_P350234 | \|nm_001012989 | \| ubiquitin-conjugating enzyme E2N-like (UBE2NL), mRNA [NM_001012989] | 4.8517766 | 1.55E-05 | -0.425252929 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| USP22 | 23326 | A_23_P207068 | BC110499 | ubiquitin specific peptidase 22, mRNA (CDNA clone IMAGE:40027756), partial cds. [BC110499] | 9.620007 | 0.001757989 | 0.239943214 |
| Protein Folding |  |  |  |  |  |  |  |
| AHSA1 | 10598 | A_23_P117599 | NM_012111 | AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) (AHSA1), mRNA [NM_012111] | 4.744326 | 0.001122977 | 0.001122977 |
| ASF1B | 55723 | A_23_P119254 | NM_018154 | ASF1 anti-silencing function 1 homolog B (S. cerevisiae) (ASF1B), mRNA [NM_018154] | 3.5671954 | $9.48 \mathrm{E}-05$ | $9.48 \mathrm{E}-05$ |
| dNajcs | 22826 | A_32_P157192 | NM_014280 | Dnaj (Hsp40) homolog, subfamily C, member 8 (DNAJC8), mRNA [NM_014280] | 3.5431235 | 0.00625256 | 0.00625256 |
| pfon 1 | 5201 | A_32_P41127 | NM_002622 | prefoldin subunit 1 (PFDN1), mRNA [NM_002622] | 4.1542726 | 0.005784741 | 0.096757483 |
| PPIA | 5478 | A_32_P68459 | NM_021130 | peptidylprolyl isomerase A (cyclophilin A) (PPIA), mRNA [ [M_021130] | 4.4811387 | 1.95E-05 | $-0.515456986$ |
| PPIAL4 | 164022 | A_32_P61061 | NM_178230 | peptidylprolyl isomerase A (cyclophilin A)-like 4 (PPIAL4), mRNA [NM_178230] | 4.524395 | 1.31E-04 | -0.359406777 |
| Oxidative Stress |  |  |  |  |  |  |  |
| GSTM4 | 2948 | A_24_P396660 | NM_147148 | glutathione S-transferase M4 (GSTM4), transcript variant 2, mRNA [NM_147148] | 4.5142026 | 0.001594553 | 0.001594553 |
| PRDX1 | 5052 | A_23_P11995 | NM_002574 | peroxiredoxin 1 (PRDX1), transcript variant 1, mRNA [NM_002574] | 4.0355334 | 0.00231451 | -0.053466491 |
| PRDX2 | 7001 | A_23_P142045 | NM_005809 | peroxiredoxin 2 (PRDX2), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA [NM_005809] | 4.4623494 | $8.69 \mathrm{E}-05$ | 0.251570318 |
| SOD1 | 6647 | A_23_P154840 | NM_000454 | superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult)) (SOD1), mRNA [NM_000454] | 5.698108 | 4.87E-05 | -0.020962833 |
| TXNRD3 | 114112 | A_32_P170925 |  | Thioredoxin reductase 3 (Thioredoxin reductase TR2) (Fragment). [ENST00000360201] | 4.0982194 | 0.007455865 |  |
| Translation |  |  |  |  |  |  |  |
| DHPS | 1725 | A_23_P501887 | NM_013407 | deoxyhypusine synthase (DHPS), transcript variant 3, mRNA [NM_013407] | 3.9081845 | 0.003835373 | 0.003835373 |
| оонн | 83475 | A_23_P125408 | NM_031304 | deoxyhypusine hydroxylase/monooxygenase (DOHH), mRNA [NM_031304] | 3.8361614 | 0.001960568 | 0.001960568 |
| EIF1 | 10209 | A_32_P53049 | NM_005801 | eukaryotic translation initiation factor 1 (EIF1), mRNA [NM_005801] | 4.1642256 | 3.83E-04 | 3.83E-04 |
| EIF4H | 7458 | A_24_P149390 | NM_031992 | eukaryotic translation initiation factor 4H (EIF4H), transcript variant 2, mRNA [NM_031992] | 4.375157 | 0.007858049 | 0.007858049 |
| PAIP2B | 400961 | A_24_P860797 |  | CDNA FL37016 fis, clone BRACE2010632. [AK094335] | 4.1392784 | $2.67 \mathrm{E}-04$ | N.I. |
| DNA Repair |  |  |  |  |  |  |  |
| CINP | 51550 | A_23_P88134 | NM_032630 | cyclin-dependent kinase 2-interacting protein (CINP), mRNA [NM_032630] | 5.064411 | 5.98E-05 | 5.98E-05 |
| MGMT | 4255 | A_23_P104323 | NM_002412 | O-6-methylguanine-DNA methyltransferase (MGMT), mRNA [NM_002412] | 3.5433805 | 2.48E-05 | -0.042636253 |
| NSMCE1 | 197370 | A_23_P95823 | NM_145080 | non-SMC element 1 homolog (S. cerevisiae) (NSMCE1), mRNA [NM_145080] | 3.512327 | 0.006473885 | -0.28311469 |
| TYMS | 7298 | A_23_P50096 | NM_001071 | thymidylate synthetase (TYMS), mRNA [NM_001071] | 5.172912 | 6.59E-05 | -0.029334326 |
| Immune Function |  |  |  |  |  |  |  |
| BST1 | 683 | A_23_P7325 | NM_004334 | bone marrow stromal cell antigen 1 (BST1), mRNA [NM_004334] | 4.3530526 | 0.009666925 | 0.009666925 |
| DBNL | 28988 | A_24_P43681 | NM_014063 | drebrin-like (DBNL), transcript variant 1, mRNA [NM_014063] | 4.0787334 | 0.001101922 | 0.001101922 |
| TNIP1 | 10318 | A_23_P19036 | NM_006058 | TNFAIP3 interacting protein 1 (TNIP1), mRNA [NM_006058] | 4.310057 | 3.49E-04 | -0.110491034 |
| TYK2 | 7297 | A_23_P141917 | NM_003331 | tyrosine kinase 2 (TYK2), mRNA [NM_003331] | 4.161575 | 0.001457419 | 0.029139847 |
| Cell Adhesion |  |  |  |  |  |  |  |
| JAM3 | 83700 | A_23_P217998 | NM_032801 | junctional adhesion molecule 3 (JAM3), mRNA [NM_032801] | 3.6390152 | 0.01173648 | -0.145035888 |
| SH3PXD2A | 9644 | A_23_P345220 | NM_014631 | SH3 and PX domains 2A (SH3PXD2A), mRNA [NM_014631] | 7.402252 | 0.005191974 | -0.569549557 |
| SPA17 | 53340 | A_23_P104876 | NM_017425 | sperm autoantigenic protein 17 (SPA17), mRNA [NM_017425] | 3.538727 | 0.001317423 | 0.49505745 |
| Other Biological Processes |  |  |  |  |  |  |  |
| ABHD11 | 83451 | A_23_P362712 | \|NM_148912 | abhydrolase domain containing 11 (ABHD11), mRNA [NM_148912] | 4.131526 | 3.22E-04 | 3.22E-04 |
| ACOT8 | 10005 | A_23_P143218 | NM_005469 | acyl-CoA thioesterase 8 (ACOT8), transcript variant 1, mRNA [NM_005469] | 3.720359 | $2.13 \mathrm{E}-06$ | 2.13E-06 |
| ADA | 100 | A_23_P210482 | NM_000022 | adenosine deaminase (ADA), mRNA [ NM _000022] | 4.4052896 | 3.22E-04 | 3.22E-04 |
| ADPRHL2 | 54936 | A_23_P34568 | NM_017825 | ADP-ribosylhydrolase like 2 (ADPRHL2), mRNA [NM_017825] | 3.6460505 | 0.009126779 | 0.009126779 |
| aKR7A3 | 22977 | A_23_P103968 | NM_012067 | aldo-keto reductase family 7 , member A3 (aflatoxin aldehyde reductase) (AKR7A3), mRNA [NM_012067] | 3.9732635 | $2.38 \mathrm{E}-04$ | $2.38 \mathrm{E}-04$ |
| ALDH3A2 | 4 | A_23_P129896 | NM_000382 | aldehyde dehydrogenase 3 family, member A2 (ALDH3A2), transcript variant 2, mRNA [NM_000382] | 4.423245 | 0.003354911 | 0.003354911 |
| ATP6V1C2 | 245973 | A_24_P276932 | NM_144583 | ATPase, $\mathrm{H}+$ transporting, lysosomal 42kDa, V1 subunit C2 (ATP6V1C2), transcript variant 2, mRNA [NM_144583] | 3.7277849 | 0.009451731 | 0.009451731 |
| C11orf60 | 56912 | A_23_P116207 | NM_020153 | chromosome 11 open reading frame 60 (C11orf60), mRNA [NM_020153] | 3.678062 | 0.003257254 | 0.003257254 |
| CA8 | 7 | A_23_P83838 | NM_004056 | carbonic anhydrase VIII (CA8), mRNA [NM_004056] | 3.502614 | 0.00188713 | 0.00188713 |
| CYB5R3 | 727 | A_24_P100277 | NM_007326 | cytochrome b5 reductase 3 (CYB5R3), transcript variant S, mRNA [NM_007326] | 3.940876 | 0.001437201 | 0.001437201 |
| DHDH | 27294 | A_23_P67367 | NM_014475 | dihydrodiol dehydrogenase (dimeric) (DHDH), mRNA [NM_014475] | 4.744879 | 2.37E-04 | 2.37E-04 |
| GK5 | 256356 | A_23_P347562 | NM_001039547 | glycerol kinase 5 (putative) (GK5), mRNA [NM_001039547] | 3.8566892 | 0.008392108 | 0.008392108 |
| GMPPB | 29925 | A_23_P92202 | NM_021971 | GDP-mannose pyrophosphorylase B (GMPPB), transcript variant 2, mRNA [NM_021971] | 3.882554 | 0.002558592 | 0.002558592 |
| GRAP | 10750 | A_23_P49638 | NM_006613 | GRB2-related adaptor protein (GRAP), mRNA [NM_006613] | 4.054854 | 2.94E-05 | 2.94E-05 |
| GRB2 | 2885 | A_24_P39654 | NM_002086 | growth factor receptor-bound protein 2 (GRB2), transcript variant 1, mRNA [NM_002086] | 4.5788116 | 0.003430953 | 0.003430953 |
| IMPAD1 | 54928 | A_24_P240732 | NM_017813 | inositol monophosphatase domain containing 1 (IMPAD1), mRNA [NM_017813] | 6.9755464 | $6.40 \mathrm{E}-04$ | 0.135935915 |
| LYPLA2 | 11313 | A_24_P276490 | NM_007260 | lysophospholipase II (LYPLA2), mRNA [NM_007260] | 5.225022 | 0.008499536 | -0.078183226 |
| NECAP2 | 55707 | A_24_P302332 | NM_018090 | NECAP endocytosis associated 2 (NECAP2), mRNA [ NM _018090] | 3.9905655 | 0.002929441 | 0.499318836 |
| NUDT11 | 55190 | A_24_P345002 | NM_018159 | nudix (nucleoside diphosphate linked moiety X)-type motif 11 (NUDT11), mRNA [NM_018159] | 3.8240397 | 0.009355441 | -0.06435149 |
| ORST2 | 219464 | A_24_P307785 | AK098491 | cDNA FL25625 fis, clone STM02974. [AK098491] | 4.545266 | $5.03 \mathrm{E}-05$ | -0.140089893 |
| PEBP1 | 5037 | A_23_P13604 | NM_002567 | phosphatidylethanolamine binding protein 1 (PEBP1), mRNA [NM_002567] | 5.396274 | 1.09E-04 | 0.241636996 |
| PKD2 | 5311 | A_23_P167324 | NM_000297 | polycystic kidney disease 2 (autosomal dominant) (PKD2), mRNA [NM_000297] | 4.252228 | 0.001213257 | -0.304167678 |
| PNPO | 55163 | A_23_P89708 | NM_018129 | pyridoxamine 5'-phosphate oxidase (PNPO), mRNA [NM_018129] | 6.484336 | 5.48E-05 | $-0.360310981$ |


| \|RBks | 64080 | A_23_P9523 | \|NM_022128 | \|ribokinase (RBKS), mRNA [NM_022128] | 3.617256 | 0.001252149 | 0.286431955 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| SLC39A3 | 29985 | A_24_P160460 | NM_144564 | solute carrier family 39 (zinc transporter), member 3 (SLC39A3), transcript variant 1, mRNA [NM_144564] | 3.5092661 | 0.011392389 | 0.272708367 |
| SNX8 | 29886 | A_23_P414252 | NM_013321 | sorting nexin 8 (SNX8), mRNA [NM_013321] | 3.5666678 | $1.25 \mathrm{E}-04$ | -0.30038026 |
| TP11 | 7167 | A_32_P95739 | NM_000365 | triosephosphate isomerase 1 (TP11), mRNA [ NM _000365] | 4.4984965 | $1.42 \mathrm{E}-04$ | 0.445172593 |
| WBSCR22 | 114049 | A_23_P71014 | NM_017528 | Williams Beuren syndrome chromosome region 22 (WBSCR22), mRNA [NM_017528] | 3.6100235 | 0.002973945 | 0.019936947 |
| Function Unknown |  |  |  |  |  |  |  |
| C17orf85 | 55421 | A_24_P176572 | NM_018553 | chromosome 17 open reading frame 85 (C17orf85), mRNA [NM_018553] | 4.0953345 | 8.10E-04 | $8.10 \mathrm{E}-04$ |
| C20orf196 | 149840 | A_23_P401709 | NM_152504 | chromosome 20 open reading frame 196 (C20orf196), mRNA [NM_152504] | 4.465778 | 8.07E-04 | 8.07E-04 |
| C20orf199 | 441951 | A_32_P157385 | AK124175 | cDNA FL42181 fis, clone THYMU2031368. [AK124175] | 5.4482255 | 0.003258362 | 0.003258362 |
| C20orf43 | 51507 | A_24_P914590 | BC002769 | chromosome 20 open reading frame 43, mRNA (cDNA clone IMAGE:3615348), complete cds. [BC002769] | 3.571246 | 6.65E-04 | 6.65E-04 |
| C20orf77 | 490 | A_23_P91207 | NM_021215 | chromosome 20 open reading frame 77 (C20orf77), mRNA [NM_021215] | 6.0635233 | 0.009970715 | 0.009970715 |
| C21orf56 | 84221 | A_23_P371765 | NM_032261 | chromosome 21 open reading frame 56 (C21orf56), mRNA [NM_032261] | 3.5951922 | $2.55 \mathrm{E}-04$ | $2.55 \mathrm{E}-04$ |
| C3orf37 | 56941 | A_23_P251377 | NM_001006109 | chromosome 3 open reading frame 37 (C3orf37), transcript variant 1, mRNA [NM_001006109] | 3.54688 | 0.011563594 | 0.011563594 |
| C9orf40 | 55071 | A_24_P43876 | NM_017998 | chromosome 9 open reading frame 40 (C9orf40), mRNA [NM_017998] | 4.304017 | 3.97E-04 | 3.97E-04 |
| C9orf64 | 84267 | A_23_P60339 | NM_032307 | chromosome 9 open reading frame 64 (C9orf64), mRNA [NM_032307] | 4.6827483 | 0.001417922 | 0.001417922 |
| CCDC32 | 416 | A_32_P98975 | NM_052849 | coiled-coil domain containing 32 (CCDC32), transcript variant 2, mRNA [NM_052849] | 3.7351253 | 0.002678538 | 0.002678538 |
| СОMMD4 | 4939 | A_23_P117767 | NM_017828 | COMM domain containing 4 (COMMD4), mRNA [NM_017828] | 4.6958866 | 0.001497977 | 0.001497977 |
| CTA-126B4.3 | 27341 | A_23_P29303 | NM_015703 | CGI-96 protein (CGI-96), mRNA [NM_015703] | 4.122841 | 5.37E-04 | 5.37E-04 |
| DHRS4L1 | 728635 | A_24_P903378 |  | isolate 1261292 dehydrogenase/reductase SDR family member 4-like 1 mRNA, [GQ871922] Agilent | 3.5196078 | 0.003623696 | 0.003623696 |
| FAM102B | 284611 | A_24_P237927 | NM_001010883 | family with sequence similarity 102, member B (FAM102B), mRNA [NM_001010883] | 3.6320534 | 0.003446399 | 0.003446399 |
| FAM103A1 | 40 | A_23_P65712 | NM_031452 | family with sequence similarity 103, member A1 (FAM103A1), mRNA [NM_031452] | 4.145468 | 6.72E-06 | 6.72E-06 |
| FAM63B | 54629 | A_24_P392333 | NM_001040453 | family with sequence similarity 63, member B (FAM63B), transcript variant 2, mRNA [NM_001040453] | 4.2302322 | 6.88E-04 | 6.88E-04 |
| FU32658 | 147872 | A_23_P431284 | NM_144688 | hypothetical protein FU32658 (FU32658), mRNA [NM_144688] | 3.6755083 | 0.001644313 | 0.001644313 |
| HN1 | 51155 | A_23_P100632 | NM_001002033 | hematological and neurological expressed 1 (HN1), transcript variant 3, mRNA [NM_001002033] | 3.6078517 | 6.04E-04 | N.I. |
| KIAA0241 | 3080 | A_24_P272967 | NM_015060 | KIAA0241 (KIAA0241), mRNA [NM_015060] | 4.4414825 | 0.001038222 | -0.074528231 |
| LXX1L | 128077 | A_23_P342744 | NM_153713 | Lix1 homolog (mouse)-like (LXX1L), mRNA [NM_153713] | 3.5574625 | 0.00178892 | 0.347932557 |
| LRRC37A2 | 474170 | A_24_P666482 | NM_001006607 | leucine rich repeat containing 37, member A2 (LRRC37A2), mRNA [NM_001006607] | 3.6066716 | 0.005008937 | 0.095475878 |
| MIAT | 440823 | A_24_P595223 | NR_003491 | myocardial infarction associated transcript (non-protein coding) (MIAT) on chromosome 22 [NR_003491] | 3.890917 | 1.20E-04 |  |
| NBPF15 | 284565 | A_32_P171181 | NM_173638 | neuroblastoma breakpoint family, member 15 (NBPF15), mRNA [NM_173638] | 3.9074104 | 0.00402691 | -0.066741306 |
| NOL7 | 51406 | A_23_P82068 | NM_016167 | nucleolar protein 7, 27kDa (NOL7), mRNA [NM_016167] | 4.034611 | $2.54 \mathrm{E}-04$ | 0.05051315 |
| OTUD3 | 23252 | A_24_P8575 | AB007928 | mRNA for KIAA0459 protein, partial cds. [AB007928] | 5.1292386 | 0.00425537 | -0.140089893 |
| PNMA6A | 84968 | A_23_P84892 | NM_032882 | paraneoplastic antigen like 6A (PNMA6A), mRNA [NM_032882] | 3.7837152 | 0.002480922 | 0.198139089 |
| STOX2 | 56977 | A_23_P251364 | NM_020225 | storkhead box 2 (STOX2), mRNA [NM_020225] | 3.699861 | 0.002620557 | 0.356154185 |
| TAGLN2 | A | A_32_P194848 | NM_003564 | transgelin 2 (TAGLN2), mRNA [NM_003564] | 3.7862806 | 0.001943818 | 0.030681935 |
| TPD52L2 | 165 | A_23_P131771 | NM_199360 | tumor protein D52-like 2 (TPD52L2), transcript variant 1, mRNA [NM_199360] | 5.294338 | 0.001024691 | -0.020674294 |
| YIPF4 | 84272 | A_23_P424080 | NM_032312 | Yip1 domain family, member 4 (YIPF4), mRNA [NM_032312] | 4.895983 | 0.001400962 | 0.043654987 |
| ZMAT2 | 153527 | A_24_P226248 | NM_144723 | zinc finger, matrin type 2 (ZMAT2), mRNA [NM_144723] | 4.33067 | 0.006994322 | 0.009221831 |

Table S3 Oligonucleotides used in this study, related to Experimental Procedures

| Primers for RT-PCR screening |  |  |
| :---: | :---: | :---: |
| Primer name |  | Sequence 5'-3' |
| RT-1 |  | GCTAAATACGACTCACTATAGGGATCCNNNNSACG ( $\mathrm{N}=\mathrm{A}, \mathrm{C}, \mathrm{G}$, or $\mathrm{T}, \mathrm{S}=\mathrm{C}$ or G ) |
| HA-specific |  | TATCCGTACGACGTCCCAGACTAC |
| RT-0 |  | GCTAAATACGACTCACTATAGGG |
| Primers for qRT-PCR of polysomal RNAs |  |  |
| Primer name |  | Sequence 5'-3' |
| GUSB | Forward Reverse | TGCCATCGTGTGGGTGAATG CCCTCATGCTCTAGCGTGTC |
| HIST2H3A | Forward Reverse | CAAGGCCCCGAGGAAGCAGCTG AGGGCAGCTTGCGGATCAGCAG |
| MRPL49 | Forward Reverse | CCACCCAACCTGCCTTACTTT TGTCCTTGTAGACGGGGATGT |
| NDUFS5 | Forward Reverse | TGCACATGGAATCGGTTATACTC CCTTCCTTTATCAGCTTATCCCG |
| Primers for qRT-PCR of mtDNA quantitation |  |  |
| Primer name |  | Sequence 5'-3' |
| Human ND1 | Forward Reverse | CCCTAAAACCCGCCACATCT GAGCGATGGTGAGAGCTAAGGT |
| Human hemoglobin | Forward Reverse | GTGCACCTGACTCCTGAGGAGA CCTTGATACCAACCTGCCCAG |
| Mouse COX2 | Forward Reverse | GCCGACTAAATCAAGCAACA CAATGGGCATAAAGCTATGG |
| Mouse $\beta$-globin | Forward Reverse | GAAGCGATTCTAGGGAGCAG GGAGCAGCGATTCTGAGTAGA |
| Primers for qRT-PCR of luciferase mRNA quantitation |  |  |
| Primer name |  | Sequence 5'-3' |
| FFluc | Forward Reverse | AGGTGGCTCCCGCTGAAT CATCGTCTTTCCGTGCTCCA |
| 18S rRNA | Forward Reverse | CGGCGACGACCCATTCGAAC GAATCGAACCCTGATTCCCCGTC |

Table S4. Antibodies used in this study, related to Experimental Procedures

| Supplier | Antigen | Species | Cat. No |
| :---: | :---: | :---: | :---: |
| Aviva Systems Biology | ATP5G2 | rabbit polyclonal | ARP40228_P050 |
| Bioworld Technology | NDUFA8 | rabbit polyclonal | BS3336 |
| Bethyl Laboratories | 4E-BP1 | rabbit polyclonal | BL895 |
|  | elF4B | rabbit polyclonal | A301-767A |
|  | rictor | goat polyclonal | A300-506A |
| Cell Signaling Technology | eIF4A | rabbit monoclonal | 2013 |
|  | elF4E | rabbit polyclonal | 9742 |
|  | Lats1 | rabbit monoclonal | 3477 |
|  | Mst1 | rabbit polyclonal | 3682 |
|  | Mst2 | rabbit polyclonal | 3952 |
|  | Myc-tag | mouse monoclonal | 2273 |
|  | phospho-4E-BP1 (S65) | rabbit polyclonal | 9451 |
|  | phospho-4E-BP1 (T37/T46) | rabbit monoclonal | 2855 |
|  | phospho-mTOR (S2448) | rabbit polyclonal | 2971 |
|  | phospho-mTOR (S2481) | rabbit polyclonal | 2974 |
|  | phospho-S6 ribosomal protein (S235/S236) | rabbit monoclonal | 4857 |
|  | phospho-S6 ribosomal protein (S240/S244) | rabbit monoclonal | 2215 |
|  | raptor | rabbit monoclonal | 2280 |
|  | S6 ribosomal protein | rabbit monoclonal | 2217 |
| GeneTex | NDUFS5 | rabbit polyclonal | 101829 |
| Proteintech | MRPL49 | rabbit polyclonal | 15542-1-AP |
| Santa Cruz Biotechnology | elF3b | goat polyclonal | sc-16377 |
|  | elF4G | goat polyclonal | sc-9602 |
|  | FRAP/mTOR | goat polyclonal | sc-1549 |

## SUPPLEMENTAL EXPERIMENTAL PROCEDURES

## Cell Culture and Plasmid Transfection

Plasmids expressing Myc-tagged or EGFP-tagged Largen or other proteins were constructed in the pcDNA3 and/or pIRES2-EGFP vectors according to standard subcloning procedures. Jurkat cells were cultured in RPMI1640 medium supplemented with $10 \%$ FBS and antibiotics. HeLa, U2-OS, and 293T cells were cultured in DMEM supplemented with $10 \%$ FBS and antibiotics. All cells were incubated in a humidified chamber at $37^{\circ} \mathrm{C}$ in $5 \% \mathrm{CO}_{2}$. Transfection of plasmids or siRNA into the above cells was performed using Lipofectamine 2000 (Invitrogen) in Opti-MEM supplemented with 10\% FBS without antibiotics and according to the manufacturer's instructions. Unless otherwise noted, cells were cultured for 2 days after transfection before use in reporter assays or for protein extractions. Stable 293T transformants were selected by culture in the presence of Geneticin (Gibco) at $0.6 \mathrm{mg} / \mathrm{ml}$. To ensure a higher frequency of cells expressing the transgene, GFP-positive cells among stable transformants were isolated by FACS.

## Preparation of Cell Lysates and Immunoblotting

Cells $\left(\sim 10^{7}\right)$ were washed twice with PBS(-), transferred into a microtube, and resuspended in CHAPS Lysis Buffer containing 40 mM HEPES (pH 7.5), $120 \mathrm{mM} \mathrm{NaCl}, 1$ mM EDTA, $0.3 \%$ CHAPS, $50 \mathrm{mM} \mathrm{NaF}, 1.5 \mathrm{mM} \mathrm{Na}{ }_{3} \mathrm{VO}_{4}, 10 \mathrm{mM}$ glycerophosphate, 10 mM pyrophosphate, and 1 mM PMSF. Tubes were rocked at $4^{\circ} \mathrm{C}$ for 10 min and centrifuged at
$10,000 \mathrm{Xg}$ for 10 min at $4^{\circ} \mathrm{C}$. Supernatants were recovered as the cell lysates, which were snap-frozen on dry ice and stored at $-80^{\circ} \mathrm{C}$ until used in experiments.

For immunoblotting, equal amounts of protein ( $\sim 20-40 \mu \mathrm{~g}$ ) were fractionated on SDS-PAGE under reducing conditions and transferred onto a PVDF membrane. Proteins of interest were identified using the primary antibodies listed in Table S4. Primary antibodies were then visualized by incubation for 1 hr with the appropriate secondary antibodies, which were: horseradish peroxidase-conjugated secondary antibody, HRP-labeled goat anti-rabbit lgG (cat.\#JM-6401-05), and rabbit anti-mouse IgG (cat.\#JM-6402-05) (both from from MBL International); and donkey anti-goat IgG-HRP (cat.\#sc-2056) (Santa Cruz Biotechnology). Bands were detected using ECL-Plus (GE Healthcare).

## Polysome Fractionation and Microarray Analysis

Cytoplasmic extracts prepared from exponentially-growing 293T cell clones were centrifuged on pre-chilled 10-50\% sucrose gradients at $35,000 \mathrm{rpm}$ for 2 hr at $4^{\circ} \mathrm{C}$ in a Beckman SW40Ti rotor, as described previously (Mamane et al., 2007; Dowling et al., 2010). Gradients were fractionated and the UV-absorbance at 254 nm was continuously recorded using an ISCO fractionator (Teledyne ISCO). Light and heavy polysome fractions were prepared from three independent sucrose gradient fractionations, and RNA from each fraction was isolated using Trizol (Invitrogen). RNA was subjected to microarray analysis at the UHN Microarray Centre (http://www.microarrays.ca/) using Whole Human

Genome 4x44k arrays (Agilent Technologies). The unpaired Student t-test was used to evaluate differences in mRNA levels between the heavy and light polysome groups, and the Benjamini \& Hochberg FDR method (Benjamini and Hochberg, 1995) was used for multiple testing corrections. A list of genes exhibiting a fold-change $>3.5$ (using corrected $p<0.05$ ) was compared between parental control cells and 2D10 cells to create Table S2.

## Quantitative Real-Time PCR (qRT-PCR)

RNA from individual sucrose gradient fractions was isolated using Trizol (Invitrogen). Purified RNA ( $1 \mu \mathrm{~g}$ ) was subjected to reverse transcription (RT) using the iScript cDNA Synthesis Kit (BIO-RAD) according to the manufacturer's instructions. Equal amounts of each RT reaction were amplified on a 7900 HT Fast Real-Time PCR System (Applied Biosystems) using Power SYBR Green PCR Master Mix (Applied Biosystems) and the primer sets listed in Table S3. Relative quantitation of the abundance of an mRNA in a given polysome fraction was performed using the $\Delta \Delta \mathrm{Ct}$ method. Values were normalized to the value obtained for each mRNA in the corresponding input RNA.

For mitochondrial DNA/nuclear DNA quantitation, genomic DNA was purified from liver or cultured cells and serially diluted to estimate the range of templates necessary for linear amplification. Typically, 8-32 ng of genomic DNA was used for qRT-PCR, which was performed as described above using the primer sets listed in Table S3.

For luciferase mRNA quantitation, total RNAs were purified from transfected cells using the NucleoSpin RNAll kit (Macherey-Nagel) and converted to $1^{\text {st }}$ strand cDNAs as
described above. qRT-PCR was performed as described above using the primer sets listed in Table S3.

## Purification of Mitochondria

Mitochondria were isolated from cultured cells or mouse liver using the Mitochondria Isolation Kit for Cultured Cells or Tissue (Thermo Scientific), respectively, following the manufacturer's instructions. Mitochondrial pellets were resuspended in 1xTBS containing $2 \%$ CHAPS followed by centrifugation at $20,000 \times \mathrm{g}$ for 2 min at $4^{\circ} \mathrm{C}$. Supernatants were recovered as mitochondrial protein extracts and subjected to immunoblotting as described above.

## Mitochondrial Mass Measurement

Cells were stained with 50 nM Mitotracker Red FM or Mitotracker Green FM (Invitrogen) in PBS buffer at $37^{\circ} \mathrm{C}$ for 15 min , followed by washing and resuspension in PBS. Samples were evaluated on a FACSCalibur (BD Biosciences) and data were analyzed with CellQuest Pro version 5.2 software (BD Biosciences). The mean fluorescence intensity in the FL1 or FL3 channel was used as an estimate of mitochondrial mass.

## Immunocytochemistry

Cells $\left(2 \times 10^{5}\right)$ of individual 293T clones were seeded in a glass bottom 35 mm dish, cultured overnight, washed with $\mathrm{PBS}(-)$, and fixed in $4 \%$ formaldehyde. To visualize
mitochondria and nuclei, cells were counterstained with Mitotracker Red FM (Invitrogen) and 4',6-diamino-2-phenylindole (DAPI) (Invitrogen). Microscopic observations were made and photographic images captured using an Olympus confocal microscope (FV1000).

## Oxygen Consumption Rate

Measurement of oxygen consumption was performed using a Seahorse XF96 analyzer (Seahorse Bioscience). Exponentially-growing Jurkat and 2D10 cells were collected by centrifugation, resuspended in unbuffered RPMI1640 medium, and seeded at $1.5 \times 10^{5}$ cells/well in XF96 plates precoated with CELL-TAK (BD Biosciences). Cells were equilibrated in unbuffered medium for 45 min at $37^{\circ} \mathrm{C}$ in a $\mathrm{CO}_{2}$-free incubator prior to transfer to the XF96 analyzer. The basal oxygen consumption rate (OCR) was measured before sequential injections of $1 \mu \mathrm{M}$ (final concentration) oligomycin (Sigma-Aldrich) were applied to halt ATP synthesis (negative control).

## ATP Measurement

Total ATP levels in cells $\left(4 \times 10^{5}\right)$ of individual 293 clones were measured by chemiluminescence using the ATPlite ATP detection kit (Perkin Elmer) according to the manufacturer's protocol. Absolute ATP levels were determined using an ATP standard curve established in parallel in each 96-well plate assayed.

## Cell Cycle Analysis

For cell cycle and proliferation analyses, BrdU incorporation was assessed using the APC BrdU Flow Kit (BD Pharmingen). Briefly, Jurkat or 2D10 cells were seeded in 6-well plates ( $1 \times 10^{5} / \mathrm{well}$ ) and cultured with or without $1 \mu \mathrm{~g} / \mathrm{ml}$ DOX. After $24 \mathrm{hrs}, 10 \mu \mathrm{M}$ BrdU was added to each well for an additional 30 min incubation. Cells were then fixed and immunostained according to the manufacturer's protocol. Flow cytometric analysis of incorporated BrdU was performed using a FACSCalibur (BD Biosciences) and FlowJo software (Tree Star).

## SUPPLEMENTAL REFERENCES

Benjamini, Y., and Hochberg, Y. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B 57, 289-300.

Dowling, R.J., Topisirovic, I., Alain, T., Bidinosti, M., Fonseca, B.D., Petroulakis, E., Wang, X., Larsson, O., Selvaraj, A., Liu, Y., Kozma, S.C., Thomas, G., and Sonenberg, N. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328, 1172-1176.

Mamane, Y., Petroulakis, E., Martineau, Y., Sato, T.A., Larsson, O., Rajasekhar, V.K., and Sonenberg, N. (2007) Epigenetic activation of a subset of mRNAs by elF4E explains its effects on cell proliferation. PLoS One 2, e242.


[^0]:    *1 Sequenced tag was asigned in the noncoding region between the genes indicated.
    *2 Cytogenetic Cordinates

